Cargando…

Bispecific human IL2‐CCR4 immunotoxin targets human cutaneous T‐cell lymphoma

The majority of clinically diagnosed cutaneous T‐cell lymphomas (CTCL) highly express the cell‐surface markers CC chemokine receptor 4 (CCR4) and/or CD25. Recently, we have developed diphtheria toxin‐based recombinant Ontak®‐like human IL2 fusion toxin (IL2 fusion toxin) and anti‐human CCR4 immunoto...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Haoyu, Wang, Zhaohui, Zhang, Huiping, Qi, Zeng, Johnson, Ariel C., Mathes, David, Pomfret, Elizabeth A., Rubin, Erin, Huang, Christene A., Wang, Zhirui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7191189/ https://www.ncbi.nlm.nih.gov/pubmed/32107846 http://dx.doi.org/10.1002/1878-0261.12653

Ejemplares similares

CCR4‐IL2 bispecific immunotoxin is more effective than brentuximab for targeted therapy of cutaneous T‐cell lymphoma in a mouse CTCL model
por: Wang, Zhaohui, et al.
Publicado: (2023)

Dosing optimization of CCR4 immunotoxin for improved depletion of CCR4(+) Treg in nonhuman primates
por: Wang, Zhaohui, et al.
Publicado: (2018)

Diphtheria toxin‐based anti‐human CD19 immunotoxin for targeting human CD19(+) tumors
por: Zheng, Qian, et al.
Publicado: (2017)

EGF-IL2 bispecific and bivalent EGF fusion toxin efficacy against syngeneic head and neck cancer mouse models
por: Qiu, Yue, et al.
Publicado: (2022)

A novel diphtheria toxin‐based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma
por: Qi, Zeng, et al.
Publicado: (2021)

Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors
por: Pilbeam, Kristy, et al.
Publicado: (2017)

Human Anti-CCR4 Minibody Gene Transfer for the Treatment of Cutaneous T-Cell Lymphoma
por: Han, Thomas, et al.
Publicado: (2012)

A novel bispecific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells to target blood vessels and vasculogenic mimicry of malignant gliomas
por: Zhang, Yonghong, et al.
Publicado: (2015)

Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies
por: Schmohl, Joerg U., et al.
Publicado: (2018)

Synergistic immunotoxin-paclitaxel combination against lymphoma
por: Müller, Fabian
Publicado: (2017)

Novel EGFR-bispecific recombinant immunotoxin based on cucurmosin shows potent anti-tumor efficiency in vitro
por: Zhang, Caiyun, et al.
Publicado: (2021)

A fully humanized IgG-like bispecific antibody for effective dual targeting of CXCR3 and CCR6
por: Robert, Remy, et al.
Publicado: (2017)

A Novel Bispecific Immunotoxin Delivered by Human Bone Marrow-Derived Mesenchymal Stem Cells to Target Blood Vessels and Vasculogenic Mimicry of Malignant Gliomas [Retraction]
Publicado: (2021)

CCR8 is a new therapeutic target in cutaneous T-cell lymphomas
por: Giustiniani, Jérôme, et al.
Publicado: (2022)

Histone modification enhances the effectiveness of IL-13 receptor targeted immunotoxin in murine models of human pancreatic cancer
por: Fujisawa, Toshio, et al.
Publicado: (2011)

CD3e-immunotoxin spares CD62L(lo) Tregs and reshapes organ-specific T-cell composition by preferentially depleting CD3e(hi) T cells
por: Kim, Shihyoung, et al.
Publicado: (2022)

Comparison of CD3e Antibody and CD3e-sZAP Immunotoxin Treatment in Mice Identifies sZAP as the Main Driver of Vascular Leakage
por: Kim, Shihyoung, et al.
Publicado: (2022)

Immunotoxin Therapy for Lung Cancer
por: Xie, Li-Yi, et al.
Publicado: (2017)

Immunotoxins: experimental design
por: Dall, P, et al.
Publicado: (2001)

Immunotoxins: The Role of the Toxin (†)
por: Antignani, Antonella, et al.
Publicado: (2013)

Countering immunotoxin immunogenicity
por: Flavell, David J
Publicado: (2016)

Immunotoxin – a new treatment option in patients with relapsed and refractory Hodgkin lymphoma
por: Novakovic, Barbara Jezersek
Publicado: (2015)

Variants selected by treatment of human immunodeficiency virus-infected cells with an immunotoxin
Publicado: (1990)

Augmentation of Saporin-Based Immunotoxins for Human Leukaemia and Lymphoma Cells by Triterpenoid Saponins: The Modifying Effects of Small Molecule Pharmacological Agents
por: Smith, Wendy S., et al.
Publicado: (2019)

Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy
por: Bokori-Brown, Monika, et al.
Publicado: (2018)

Disruption of CCL20-CCR6 interaction inhibits metastasis of advanced cutaneous T-cell lymphoma
por: Ikeda, Sho, et al.
Publicado: (2016)

Treatment of solid tumors with immunotoxins
por: Messmer, Davorka, et al.
Publicado: (2005)

Bouganin, an Attractive Weapon for Immunotoxins
por: Bortolotti, Massimo, et al.
Publicado: (2018)

Effect of Chemokine Receptors CCR7 on Disseminated Behavior of Human T cell Lymphoma: clinical and experimental study
por: Yang, Jing, et al.
Publicado: (2011)

Cytotoxins and immunotoxins for cancer therapy : clinical applications /
Publicado: (2005)

IL-31 and IL-8 in Cutaneous T-Cell Lymphoma: Looking for Their Role in Itch
por: Abreu, Maria, et al.
Publicado: (2021)

Immunotoxins: From Design to Clinical Application
por: Kreitman, Robert J., et al.
Publicado: (2021)

Toxin and Immunotoxin Based Therapeutic Approaches
por: Bortolotti, Massimo, et al.
Publicado: (2022)

The state of the art of bispecific antibodies for treating human malignancies
por: Wang, Shuhang, et al.
Publicado: (2021)

Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma
por: Castaneda-Puglianini, Omar, et al.
Publicado: (2021)

The Effect of Small Molecule Pharmacological Agents on the Triterpenoid Saponin Induced Endolysosomal Escape of Saporin and a Saporin-Based Immunotoxin in Target Human Lymphoma Cells
por: Wensley, Harrison J., et al.
Publicado: (2021)

Clinical and preclinical tolerance protocols for vascularized composite allograft transplantation
por: Yang, Jerry Huanda, et al.
Publicado: (2021)

Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin
por: Flavell, D J, et al.
Publicado: (2001)

The Development and Characterization of a Human Mesothelioma In Vitro 3D Model to Investigate Immunotoxin Therapy
por: Xiang, Xinran, et al.
Publicado: (2011)

Cerebellar Purkinje cells incorporate immunoglobulins and immunotoxins in vitro: implications for human neurological disease and immunotherapeutics
por: Hill, Kenneth E, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_ne1c7o8e7ata35205qg573h7el